Eisai's farletuzumab misses endpoint in first Phase III ovarian cancer data
This article was originally published in Scrip
Executive Summary
The first topline Phase III data for Eisai's next big oncology hope farletuzumab (MORAb-003) show that the folate receptor-alpha (FRA)-targeting antibody missed its progression-free survival (PFS) primary endpoint in patients with relapsed platinum-sensitive ovarian cancer.